Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Technical Presentation (December 2022)
16 slides from Cellectis's technical presentation, December 2022
Slide 1: AMELI-01: Preliminary Results from a Phase I Trial of UCART123v1.2
AMELI-01:Preliminary Results from A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia David A. Sallman1, Daniel J. DeAngelo2, Naveen Pemmaraju3, Shira Dinner4, Saar Gill5, Rebecca Olin6, Eunic
Slide 2: Background and Introduction
Background and Introduction It is estimated that 20,050 new cases and 11,540 deaths related to AML will occur in the US in 2022 Outcomes for patients with R/R AML remain poor, with response rates <30% and an expected 5-year overall survival of <15% AMELI-01 (NCT03190278) is a phase I, open-lab
Slide 3: UCART123v1.2: Allogeneic "Off-the-Shelf" T-cell Product
UCART123v1.2: Allogeneic “Off-the-Shelf” T-cell Product UCART123v1.2 (anti-CD123 scFv- 41BB-CD3ζ): CD123 is a validated therapeutic target in AML Genetically modified allogeneic T- cell product manufactured from non-HLA–matched healthy donor cells TRAC disrupted using TALEN® to eliminate TCRαβ
Slide 4: AMELI-01 Study Design
AMELI-01 Study Design Key inclusion criteria Dose-Escalation UCART123v1.2 mTPI design ● 2-4 pts/cohort Relapsed or primary refractory AML (>5% bone marrow blasts) FC Arm FCA Arm Blasts expressing CD123 PS of ≤1 and adequate organ function UCART123v1.2 UCART123v1.2 (single dose) (single dose) P
Slide 5: Baseline Characteristics
Baseline Characteristics Characteristic Total (N = 18*) Age, median (range), years 57 (18-64) Female, n (%) 8 (44) ECOG PS 1, n (%) 17 (94) ELN 2017 Classification, n (%) Adverse risk 14 (78) Intermediate risk 3 (17) Median baseline bone marrow blasts % (range) 37 (0-88) Number of prior treatments,
Slide 6: UCART123v1.2 - Related TEAEs (FC + FCA)
UCART123v1.2 - Related TEAEs (FC + FCA) FC FCA FC + FCA FC Total [n=8] FCA Total [n=9] All patients DL1=2; DL2=3; DL2i=2; DL3=1 DL2=8; DL2i=1 N=17* TEAE, n Any grade Gr ≥3 Any grade Gr ≥3 Any grade Gr ≥3 CRS 8 2 9 2 17 4 HLH 1 1 1 0 2 1 ICANS 1 1 1 0 2 1 ALT increased 4 1 1 1 5 2 AST increased 4 1 1
Slide 7: UCART123v1.2 - Serious TEAEs (All Cause – FC + FCA)
UCART123v1.2 - Serious TEAEs (All Cause – FC + FCA) FC FCA FC + FCA FC Total [n=8] FCA Total [n=9] Total patients DL1=2; DL2=3; DL2i=2; DL3=1 DL2=8; DL2i=1 N=17* Serious TEAE, n (%) Any grade Gr ≥3 Any grade Gr ≥3 Any grade Gr ≥3 CRS 3 2 2 2 5 4 ICANS 1 1 0 0 1 1 Pneumonia 1 1 1 1 2 2 Pneumonia fung
Slide 8: Anti-Leukemic Activity Observed in 4/17 Patients at DL2 and Above
Anti-Leukemic Activity Observed in 4/17 Patients at DL2 and Above 100 FC Arm FC arm 90 102-201 80 104-204 DL1 • Patient 101-219 (DL2i): SD % of Blasts in BM 70 60 101-209 • Patient 103-223 (DL2i): MLFS 50 102-208 DL2 40 30 103-207 20 101-219 10 0 103-223 DL2i -10 103-211 DL3 Screening D14 D28 FCA
Slide 9: Addition of Alemtuzumab Results in Prolonged Lymphodepletion
Addition of Alemtuzumab Results in Prolonged Lymphodepletion Absolute Lymphocyte Counts FC Arm FCA Arm 10 10 102-201 102-222 5 DL1 5 104-204 103-225 2.0 2.0 101-209 103-231 ALC (K/µL) ALC (K/µL) 1.5 102-208 DL2 1.5 104-218 DL2 1.0 103-207 1.0 104-224 101-219 104-226 0.5 DL2i 0.5 103-223 114-229 0.0
Slide 10: Addition of Alemtuzumab Results in Increased UCART123v1.2 Expansion
Addition of Alemtuzumab Results in Increased UCART123v1.2 Expansion UCART123 Cell Expansion in WB by VCN VCN AUC(0-28days) 1000000 FC Arm 102-201 100000 DL1 104-204 100 Psi copies/µg DNA 101-209 10000 (days x copies/ug of DNA) 102-208 DL2 1000 103-207 80 100 101-219 DL2i VCN - AUC LLOQ 10 103-223 60
Slide 11: Cytokine Secretion and Ferritin Levels Correlated with Cell Expansion
Cytokine Secretion and Ferritin Levels Correlated with UCART123v1.2 Cell Expansion Cytokine Profile of All Patients from FCA Arm IL-2 IL-6 IFN-γ TNF-α 10 10000 1000 10 1000 100 Fold change 100 1 10 1 10 1 1 0.1 0.1 0.1 0.1 11 14 17 21 25 28 35 64 0 1 2 4 5 7 9 11 14 17 21 25 28 35 64 0 1 2 4 5 7 9 1
Slide 12: Patient 104-226 Achieved a Durable MRD Negative CR
Patient 104-226 Achieved a Durable MRD Negative CR Clinical Characteristics Age, Race, Sex 64 year old white female ECOG 1 ELN 2017 Classification; WHO Classification Adverse risk; AML with myelodysplasia-related changes Cytogenetic and Molecular Abnormalities 45,XX,-7,t(10;12)(q24;p13)[5]; IDH1, EZ
Slide 13: Translational Data Supports Use of a Two-Dose Regimen of UCART123v1.2
Translational Data From Patient 104-226 and Others Supports Use of a Two-Dose Regimen of UCART123v1.2 UCART123v1.2 expansion correlates with reduction in tumor burden at DL2 (6.25 x 105 cells/kg) but at this dose, UCART123v1.2 cell function is not sufficient for sustained anti- leukemic activity i
Slide 14: AMELI-01 Amended Protocol with Two-Dose Regimen Design
AMELI-01 Amended Protocol with Two-Dose Regimen Design Dose-Escalation UCART123.1.2 mTPI design; 2-4 pts/cohort FC Arm FCA Arm UCART123v1.2 UCART123v1.2 UCART123v1.2 (single dose) (single dose) (2-dose regimen) DL 3 DL 3 DL 3 x 2 DL 2i DL 2i DL 2i x 2 DL 2 DL 2 DL 2 x 2 UCART123.v1.2 DL-1 1.25×105 c
Slide 15: Conclusions
Conclusions Adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123v1.2 cell expansion, which correlated with improved activity and cytokine profiles One patient in the DL2 FCA arm achieved >90% blast reduction at Day 28 One patient in the DL2 FCA
Slide 16: Acknowledgments
Acknowledgments We thank the patients, families, co-investigators and all study personnel who made this trial possible The AMELI-01 study is funded by Cellectis, S.A. For questions or comments, please contact Dr. David A. Sallman: David.Sallman@moffitt.org For more information, please contac